Fractyl Health is a pioneering brand focused on advancing root-cause therapies for type 2 diabetes (T2D). With a vision to develop breakthrough therapies that can prevent and reverse T2D, Fractyl Health is dedicated to combating the metabolic diseases of modernity. Despite the numerous advances in T2D treatment, it continues to be a leading cause of morbidity and mortality in the 21st century, affecting around 30 million people in the United States alone.

Fractyl Health is committed to targeting the root causes of T2D through their innovative treatments. One of the brand's key offerings is Revita®, an endoscopic procedural therapy that uses a proprietary device system. Revita® aims to remodel the lining of the duodenum, which is the body's metabolic controller, by using hydrothermal ablation.

This therapy is designed to edit abnormal nutrient sensing and signaling mechanisms that are believed to be a root cause of T2D. Fractyl Health is also working on Rejuva®, a novel pancreatic gene therapy platform that is currently in preclinical development. This platform has the potential to restore insulin production and islet function, potentially enabling long-term remission of T2D in patients with advanced disease.

By uniting biology and technology, Fractyl Health is revolutionizing the treatment of metabolic disease. Their passionate team of innovators is at the forefront of groundbreaking research and clinical studies, aiming to deliver their therapies to patients as broadly and rapidly as possible. To learn more about Fractyl Health and their transformative work in the fight against T2D, visit their website